KPTI News and Press, Karyopharm Therapeutics Inc. From 05/26/21

Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference PR Newswire NEWTON, Mass. , May 26, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today anno...

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting PR Newswire NEWTON, Mass. , May 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharma...

Antengene announces that China's National Medical Products Administration ((NMPA)) has approved the Investigational New Drug ((IND)) application for a Phase III trial to evaluate the safety and efficacy of selinexor (Xpovio) being co-developed by Karyopharm Therapeutics (KPTI) ...

Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q1 2021 Earnings Call May 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call Transcr...

Karyopharm Therapeutics Inc. (KPTI) Q1 2021 Results Earnings Conference Call May 03, 2021, 08:30 AM ET Company Participants Ian Karp - Senior Vice President, Investor and Public Relations Richard Paulson - President and Chief Executive Officer Michael Kauffman - Co-Founder, Senior Clinical Ad...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Karyopharm Therapeutics Inc. 2021 Q1 - Results - Earnings Call Presentation

Although Karyopharm Therapeutics (KPTI) saw 35% year-over-year growth in its sole product, XPOVIO (selinexor), the company still missed Q1 earnings estimates.Q1 GAAP EPS missed by $0.07 and although it increased 28.2% compared to the prior-year period, revenue missed by $2.4M.In the quarter, ...

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer -- Richard Paulson, Recent Chief Executive Officer of Ipsen North America and Former Vice President and General Manager of Oncology at Amgen, Brings Wealth of Commercial Leadership a...

Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021 -- Conference Call Scheduled for Monday, May 3, 2021, at 8:30 a.m. ET -- PR Newswire NEWTON, Mass. , April 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a com...

Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO® (selinexor) in Combination with Velcade® (bortezomib) and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma - EM...